Hemolens Diagnostics sp. z o.o.

Manufacture of medical and dental instruments and supplies

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2015-12-02
Share capital
404,000.00 PLN
Activity description

Hemolens Diagnostics develops non-invasive cardiac diagnostic software, including Cardiolens Viewer®, a cloud-based AI tool that transforms coronary CT angiography (CCTA) into a patient-specific 3D visualization and supports the identification of stenoses. Its FFR-CT Pro® technology enables detailed anatomical and functional evaluation of coronary arteries; its diagnostic methods use computational fluid mechanics.

Registered address
ul. Legnicka 48G, 54-202 Wrocław, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-69269-95203-RJVAI-22

Financials

Revenue history (in k)

From the notes

Current income tax (CIT due)$0

Filing timeliness

1 of 6 financial statements was filed late (for 2021, 91 days late). 3 of 6 audited by a statutory auditor.

  • 202508/07/2026
  • 202408/07/2025
  • 202312/07/2024
  • 202206/07/2023
  • 202114/10/2022
  • 202023/09/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Division · Other manufacturing370 / 493
Top 75%
Sector · Manufacturing9,828 / 11,958
Top 82%
City · Wrocław10,309 / 13,656
Top 75%
Voivodeship · Dolnośląskie18,636 / 23,844
Top 78%
Country · Poland231,992 / 297,266
Top 78%

Results vs industry

Revenue
This companyUSD 37.96kMedianUSD 287.80kAverageUSD 4.92m
Net profit
This companyUSD -4.88mMedianUSD 10.65kAverageUSD 206.35k
Operating costs
This companyUSD 4.86mMedianUSD 269.05kAverageUSD 4.50m
Assets
This companyUSD 26.16mMedianUSD 221.07kAverageUSD 5.78m

News

Cardiolens Viewer® with MDR certification – official handover by TÜV Rheinland

Cardiolens Viewer® with MDR certification – official handover by TÜV Rheinland

The official handover of the MDR certificate by the notified body TÜV Rheinland is an important milestone for us – confirming several years of work, many key design decisions, and the commitment of the entire Hemolens Diagnostics team. From certification to official handover In May 2026, we successfully completed the conformity assessment of Cardiolens Viewer® […]

How can technology give us more time? Hemolens Diagnostics at IT UNPLUGGED conference

How can technology give us more time? Hemolens Diagnostics at IT UNPLUGGED conference

Can technology give us more time? In healthcare, the answer is yes. More time for prevention, faster diagnosis, and more effective treatment. This idea was at the core of our participation in the IT UNPLUGGED conference in Lublin. IT UNPLUGGED – a meeting place for technology and business The IT UNPLUGGED event, organized by the […]

MDR Certified: Cardiolens Viewer® Clears a Rigorous EU Regulatory Threshold

MDR Certified: Cardiolens Viewer® Clears a Rigorous EU Regulatory Threshold

We have successfully completed the MDR (EU) 2017/745 conformity assessment procedure for Cardiolens Viewer®. The assessment was conducted by TÜV Rheinland LGA Products GmbH, a notified body registered with the European Commission under number 0197. CE marking paves the way for the commercialization of our system in the European market. What MDR certification means in […]

Shaping the Future of Interventional Cardiology at EAPCI Summit 2026

Shaping the Future of Interventional Cardiology at EAPCI Summit 2026

On 19–20 February 2026, we participated in the EAPCI Summit 2026 held in Munich, Germany. This year’s edition was guided by the theme ‘Bringing together scientific rigour, multidisciplinary expertise, and training for the next generation.’ The two-day programme created a platform for in-depth discussions on access to care, the implementation of clinical standards, and the […]

The topic of AI and innovation dominated the 4th Conference of the Polish Cardiac Society (Wroclaw Department)

The topic of AI and innovation dominated the 4th Conference of the Polish Cardiac Society (Wroclaw Department)

On February 20-21, 2026, the 4th Conference of the Polish Cardiac Society (Wroclaw Department) took place in Wrocław. The event gathered local physicians and leaders in cardiology and cardiac surgery, as well as specialists interested in the diagnosis and treatment of cardiovascular diseases. The two-day conference provided a platform for exchanging experiences and presenting the […]

Arm in arm: how in silico modelling and AI tackle the “grey zone” in coronary diagnostics

Arm in arm: how in silico modelling and AI tackle the “grey zone” in coronary diagnostics

During the latest Avicenna Alliance webinar, our team presented how combining CCTA, in silico patient‑specific modelling, and AI may help address one of the most discussed areas in coronary diagnostics – the functional “grey zone” between clearly significant and clearly non‑significant lesions. In the presentation, CSO Ziemowit Ostrowski and co‑founder Andrzej Kosior described an approach […]

Offer

  • CT angiography analysis software
  • Three-dimensional coronary artery visualization
  • Blood vessel segmentation
  • FFR-CT diagnostics
  • Blood flow modelling
Certifications: ISO 13485

Websites

The site is available in: Polish and English.

  • hemolens.comNon-invasive cardiac diagnostics – Hemolens
    WordPress 7.1ElementorHubSpotGoogle AnalyticsGoogle Tag ManagerYoast SEOWPMLLiteSpeed

Trademarks

The company holds 5 active trademarks registered with the Polish Patent Office. The first mark was filed in 2021.

MarkNumberClassesStatusProtected until
Cardiolens (word)Z.5423929, 10, 42Protected Apr 26, 2032
HEMOLENS (word)Z.5389129, 10, 42Protected Jan 21, 2032
Mark without a word element (figurative)Z.5364609, 10, 42Protected Nov 16, 2031
HEMOLENS Z.5364579, 10, 42Protected Nov 16, 2031
HEMOLENS DIAGNOSTICS Z.5364599, 10, 42Protected Nov 16, 2031
MarkProtected until
Cardiolens (word)Apr 26, 2032
HEMOLENS (word)Jan 21, 2032
Mark without a word element (figurative)Nov 16, 2031
HEMOLENS Nov 16, 2031
HEMOLENS DIAGNOSTICS Nov 16, 2031

Job offers

The company lists 1 job opening on its own careers page: hemolens.com/career.

Position
Recruitment Specialist

Authorized Representatives

Bernard Gołko age 49 – President of the Management Board
Łukasz Zontek age 44 – Członek Zarzdu
Wioletta Zboralska age 55 – Attorney-in-fact (joint)

Manner of representation

Declarations of will on behalf of the company are made by at least two members of the management board acting jointly, or by a member of the management board acting jointly with a commercial proxy.

Supervisory board

Mariusz Aleksander Waniołka age 59 – Supervisory Board Member
Robert Edward Oskard age 64 – Supervisory Board Member
Piotr Robert Lipko age 35 – Supervisory Board Member
Tomasz Piec age 57 – Supervisory Board Member

Ownership

OwnerSharesShare valueStake
Ms Galleon Gmbh
778$105,051.3296.2624%
Wojciech Tarnawski
236$3,187.472.9208%
Andrzej Kosior
33$445.710.4084%
Kryspin Mirota
33$445.710.4084%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2016-01-26.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 26,419

Public aid

7 public aid cases recorded, with a total value of $4,088,406.

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$16,968
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$16,982
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$16,652

European Funds

ProjectEU co-financing
HEMOFLOW cloud platform for non-invasive hemodynamic diagnostics
$3.4M

Competitors

Name
IQ Med sp. z o.o.
Radpal sp. z o.o.
Medapp S.A.
Idose sp. z o.o.
VERY Goof P.S.A.
Cephio sp. z o.o.
Creoox R&D sp. z o.o.
Proton Bytes sp. z o.o.
Liver Ai sp. z o.o.
Vr-Learning sp. z o.o.

Change history

DateEvent
2025-10-15Share capital increase
2025-08-27Share capital increase
2025-03-14Share capital increase
2024-10-22Share capital increase
2024-02-14Share capital increase

FAQ

Last updated: 2026-07-15